Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapy.

Søgaard, Caroline K; Nepal, Anala; Petrovic, Voin; Sharma, Animesh; Liabakk, Nina-Beate; Steigedal, Tonje S; Otterlei, Marit

Søgaard, Caroline K; Nepal, Anala; Petrovic, Voin; Sharma, Animesh; Liabakk, Nina-Beate; Steigedal, Tonje S; Otterlei, Marit.

Afiliación

Søgaard CK; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Nepal A; Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Petrovic V; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Sharma A; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Liabakk NB; Proteomics and Modomics Experimental Core Facility (PROMEC), NTNU, Trondheim, Norway.
Steigedal TS; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Otterlei M; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.

Oncotarget ; 10(68): 7185-7197, 2019 Dec 31.

Article en En | MEDLINE | ID: mdl-31921382

Palabras clave

APIM; autophagy; cancer; multi-targeting therapy; signaling pathways

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2019 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google